Dermata Therapeutics Inc. (DRMA)
Dermata Therapeutics Statistics
Share Statistics
Dermata Therapeutics has 5.43M shares outstanding. The number of shares has increased by 1122.96% in one year.
Shares Outstanding | 5.43M |
Shares Change (YoY) | 1122.96% |
Shares Change (QoQ) | 166.11% |
Owned by Institutions (%) | 38.16% |
Shares Floating | 3.99M |
Failed to Deliver (FTD) Shares | 738 |
FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 93.74K, so 4.59% of the outstanding shares have been sold short.
Short Interest | 93.74K |
Short % of Shares Out | 4.59% |
Short % of Float | 10.63% |
Short Ratio (days to cover) | 0.52 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.32. Dermata Therapeutics's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -0.32 |
PS Ratio | 0 |
Forward PS | 0.3 |
PB Ratio | 0 |
P/FCF Ratio | 0 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Dermata Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1602.58, with a Debt / Equity ratio of 0.
Current Ratio | 1602.58 |
Quick Ratio | 1602.58 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.54B |
Employee Count | 8 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -84.54% in the last 52 weeks. The beta is 0.58, so Dermata Therapeutics's price volatility has been higher than the market average.
Beta | 0.58 |
52-Week Price Change | -84.54% |
50-Day Moving Average | 1.19 |
200-Day Moving Average | 1.55 |
Relative Strength Index (RSI) | 33.17 |
Average Volume (20 Days) | 1.66M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -12.51B |
Net Income | -12.29B |
EBITDA | -12.51B |
EBIT | n/a |
Earnings Per Share (EPS) | -8032.22 |
Balance Sheet
The company has 3.16M in cash and 0 in debt, giving a net cash position of 3.16M.
Cash & Cash Equivalents | 3.16M |
Total Debt | 0 |
Net Cash | 3.16M |
Retained Earnings | -65.68B |
Total Assets | 3.53M |
Working Capital | 1.56M |
Cash Flow
In the last 12 months, operating cash flow was -11.16B and capital expenditures 0, giving a free cash flow of -11.16B.
Operating Cash Flow | -11.16B |
Capital Expenditures | 0 |
Free Cash Flow | -11.16B |
FCF Per Share | -7297.13 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
DRMA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for DRMA is $6, which is 525% higher than the current price. The consensus rating is "Buy".
Price Target | $6 |
Price Target Difference | 525% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on May 16, 2024. It was a backward split with a ratio of 1:15.
Last Split Date | May 16, 2024 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | -35.52 |
Piotroski F-Score | 2 |